AMPK-driven Macrophage Responses Are Autophagy Dependent in Experimental Bronchopulmonary Dysplasia
American Journal of Respiratory Cell and Molecular Biology · 01.03.2023 · 68 (3) · 279-287
DOI: 10.1165/rcmb.2022-0282oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, online erschienen am 01.03.2023. Verfasst von Sourabh Soni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Hyperoxia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIH.
Abstract (Originalsprache)
The pathogenesis of bronchopulmonary dysplasia (BPD) remains incompletely understood. Recent studies suggest insufficient AMP-activated protein kinase (AMPK) activation as a potential cause of impaired autophagy in rodent and nonhuman primate models of BPD. Impaired autophagy is associated with enhanced inflammatory signaling in alveolar macrophages (AMs) and increased severity of murine BPD induced by neonatal hyperoxia exposure. The goal of this study was to determine the role of autophagy and AMPK activation in macrophage responses in murine BPD. C57BL/6J mice were exposed to neonatal hyperoxia starting on postnatal day (P)1 and treated with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) between P3 and P6. Mice were euthanized on P7, and markers of AMPK activation and autophagy were assessed by immunoblotting. Alveolarization was assessed using radial alveolar counts, mean linear intercept measurements, and quantification of alveolar septal myofibroblasts. Relative mRNA expression of M1-like and M2-like genes was assessed in AMs isolated from BAL fluid from wild-type, LysMCre−-Becn1fl/fl, and LysMCre+-Becn1fl/fl mice after neonatal hyperoxia exposure. AICAR treatment resulted in AMPK activation and induction of autophagic activity in whole-lung and BAL cell lysates and attenuated hyperoxia-induced alveolar simplification in neonatal lungs. AICAR-treated control but not Beclin1-deficient AMs demonstrated significantly decreased expression of M1-like markers and significantly increased expression of M2-like markers. In conclusion, pharmacologic activation of AMPK by AICAR resulted in induction of autophagy and played a protective role, at least in part, through attenuation of proinflammatory signaling in AMs via autophagy-dependent mechanisms in a murine model of BPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
- Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China; and.
- Department of Neonatology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Förderung
- NICHD NIH HHS
- NIH
Zitieren
APA
Soni, S., Jiang, Y., Zhang, L., Thakur, A., & Cataltepe, S. (2023). AMPK-driven Macrophage Responses Are Autophagy Dependent in Experimental Bronchopulmonary Dysplasia. American Journal of Respiratory Cell and Molecular Biology, 68(3), 279-287. https://doi.org/10.1165/rcmb.2022-0282oc
Vancouver
Soni S, Jiang Y, Zhang L, Thakur A, Cataltepe S. AMPK-driven Macrophage Responses Are Autophagy Dependent in Experimental Bronchopulmonary Dysplasia. American Journal of Respiratory Cell and Molecular Biology. 2023;68(3):279-287. doi:10.1165/rcmb.2022-0282oc
BibTeX
@article{Soni2023,
author = {Soni, Sourabh and Jiang, Yujie and Zhang, Liang and Thakur, Abhijeet and Cataltepe, Sule},
title = {AMPK-driven Macrophage Responses Are Autophagy Dependent in Experimental Bronchopulmonary Dysplasia},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2023},
volume = {68},
number = {3},
pages = {279--287},
doi = {10.1165/rcmb.2022-0282oc}
}
EUVIMED